Is it Right Time Pull the Trigger on Exact Sciences Corporation [EXAS] Stock?

Exact Sciences Corporation [EXAS] shares are up more than 56.37% this year and recently increased 0.01% or $1.98 to settle at $134.85. EXAS has a short ratio of 5.48. This implies that the market is currently less bullish on the outlook for EXAS.

On 3, December 2020, Apogee Enterprises to Report Fiscal 2021 Third Quarter Financial Results. According to news published on Yahoo Finance, Apogee Enterprises, Inc. (Nasdaq: APOG) will report its fiscal 2021 third quarter results on Friday, December 18, 2020 before the market opens. The company will also host a conference call to discuss its financial results and provide a business update. This conference call will be webcast beginning at 8:00 a.m. Central Time, on December 18, 2020.

Analyst Birdseye View:

The most recent analyst activity for Exact Sciences Corporation [NASDAQ:EXAS] stock was on October 28, 2020, when it was Downgrade with a Neutral rating from Citigroup, which also raised its 12-month price target on the stock from $120 to $140. Before that, on October 29, 2020, UBS Recapitulated a Neutral rating and elevated its amount target to $140. On October 08, 2020, BTIG Research Resumed a Buy rating and boosted its price target on this stock to $140. On April 02, 2020, Evercore ISI Initiated an Outperform rating and increased its price target to $70. On January 10, 2020, BTIG Research Resumed a Buy rating and increased its price target to $127. On January 07, 2020, Citigroup Initiated a Buy rating and boosted its amount on this stock to $120. On December 13, 2019, Dougherty & Company Initiated a Buy rating and boosted its target amount on this stock to $120.

In the past 52 weeks of trading, this stock has oscillated between a low of $35.25 and a peak of $141.90. Right now, according to Wall Street analyst the average 12-month amount target is $150.43. At the most recent market close, shares of Exact Sciences Corporation [NASDAQ:EXAS] were valued at $134.85. According to the average price forecast, investors can expect a potential return of -0.29%.

FUNDAMENTAL ANALYSIS

Exact Sciences Corporation [NASDAQ:EXAS] most recently reported quarterly sales of 408.36 billion, which represented growth of 86.70%. This publicly-traded organization’s revenue is $213,210 per employee, while its income is -$20,436 per employee. This company’s Gross Margin is currently 75.50%, its Operating Margin is -33.40%, its Pretax Margin is -30.68, and its Net Margin is -9.59. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -3.34, -5.66, -7.40 and -3.64 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 29.45 and the whole liability to whole assets at 27.24. It shows enduring liability to the whole principal at 29.18 and enduring liability to assets at 0.27 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 131.62 points at 1st support level, the second support level is making up to 128.40. But as of 1st resistance point, this stock is sitting at 138.67 and at 142.49 for 2nd resistance point.

Exact Sciences Corporation [EXAS] reported its earnings at -$1.46 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.52/share signifying the difference of -0.94 and -180.80% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.58 calling estimates for -$0.63/share with the difference of 0.05 depicting the surprise of 7.90%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Exact Sciences Corporation [NASDAQ:EXAS] is 6.40. Likewise, the Quick ratio is also the same, showing Cash ratio at 1.37. Now if looking for a valuation of this stock’s amount to sales ratio it’s 13.85 and it’s amount to book ratio is 5.97.

Insider Stories

The most recent insider trade was by Conroy Kevin T, President and CEO, and it was the sale of 30577.0 shares on Dec 01. Conroy Kevin T, the President and CEO, completed a sale of 32819.0 shares on Nov 02. On Oct 01, Conroy Kevin T, President and CEO, completed a sale of 27425.0 shares.